|
| Press Releases |
|
 |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL)
Nov 29, 2024 22:45 HKT/SGT
|
|
|
Niyo Doubles Click-Through Rates and Improves Customer Retention with CleverTap 
Nov 29, 2024 22:40 HKT/SGT
|
|
|
Dmall Inc. Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Nov 29, 2024 22:30 HKT/SGT
|
|
|
Edvantage Group Announces FY2024 Annual Results
Nov 29, 2024 22:14 HKT/SGT
|
|
|
The Hong Kong Institute of Directors Announces Winners
Nov 29, 2024 21:06 HKT/SGT
|
|
|
Launch of Demonstration Test for CO2 Capture from Chemical Recovery Boilers at Paper Mills in Japan
Nov 29, 2024 19:11 JST
|
|
|
Mitsubishi Electric's Swedish Subsidiary Signs a Share Transfer Agreement to Wholly Acquire Norwegian Elevator Company ALT Heis
Nov 29, 2024 15:30 JST
|
|
|
JAL and NEC Test AI-Powered Carry-On Baggage Analysis Solution
Nov 29, 2024 15:27 JST
|
|
|
Hitachi Energy to integrate ScottishPower wind farm to power almost one million homes in the United Kingdom
Nov 29, 2024 12:54 JST
|
|
|
TGR Announces Partially Upgraded Supra (3.0-liter) and Special-edition Supra "A90 Final Edition"
Nov 29, 2024 11:22 JST
|
|
|
HEROWORKS Intensifies Collaboration with a Global Hotel IT Company
Nov 29, 2024 10:00 HKT/SGT
|
|
|
EdgePoint Infrastructure Inks Strategic Partnership with CelcomDigi to expand connectivity in Malaysia at TowerXchange Meet Up Asia 2024
Nov 29, 2024 09:30 HKT/SGT
|
|
|
Trescon's World Blockchain Summit Rebrands to HODL, Signalling a Bold New Era for Innovations in Blockchain and Beyond
Nov 28, 2024 23:26 HKT/SGT
|
|
|
Academic Labs (AAX) Selected as the Official Educational Sponsor for the 2024 World Chess Championship in Singapore
Nov 28, 2024 21:50 HKT/SGT
|
|
|
Hitachi Receives an Order for All 147 Elevators and Escalators for the Second Phase of the Taipei MRT Wanda-Zhonghe-Shulin Line
Nov 28, 2024 22:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
